shows there a future and a need for our drugs as Sir chris was the lead investor in the placing.
I disagree regards to VRP700. The first trial results we know were exceptionally good and I see no reason for anything different. They already have a good idea so that is why dosage trials are funded for the future already. Yes, I am unhappy that there is a slight delay in publication of results as I feel again if exceptionally good the sp would have again risen and the placing 2.2p would have seen even more of a bargain. Remember Sir Chris is one very good investor and a hard negotiator. Worth reading this from Oct last year! http://www.bbc.co.uk/news/uk-wales-24355533
So we got an investment, which we really needed, since we only have £300k left in our pot, and we were all concerned that there just might not be 'good news' coming. Indeed with three months RNS free waiting, for all we knew the whole thing could have gone to the wall! Now, we are pretty certain to have investment to the tune of circa £14m, and we have the best bio investor behind us and on the bod. Future trials are also promised, all to complete by end of 2015. We all knew, on thursday night, that if you nigh on double your shareholding, you will get massive dilution, and yesterday it came. BUT, it could NOT have been better. We opened at 0.675p (Not that much really, I lost that much in normal trading TWICE in the last month!), then the downside dropped further, to 0.0825p, still less than a penny. Trading went on, circa 12 x million shares traded by close of play. AND WE CLOSED DOWN 0.040p! Nearly 4.5million shares were 'Buys', with just over 7million 'Sells'. By Monday more investors will have had the time to read thoroughly and assimulate the 10 x page RNS, and will be awaiting the 'Offer Document', and I believe that most will be looking to BUY all next week, and I dare say that the sp will go over the 3.45p mark! Trust me Armyboy2, I was twenty years in the Gunners. Regards, David
Agreed not great in the short term but long term should pan out nicely. For new investor the placing range is a great entry point. Dyor always. Pk
is right. I still hold over 2 million of these having got sucked in. I suspect this deal was in mind at the time the short/medium term was quoted by the ceo as again same price as those he bought at last smaller placing. I also cannot believe that after all the publicity,TAP, Lancet, studies etc if they were first in class drugs they could not have done a better deal then this - it does not stack up. Funny also how asthma has been dropped from RPL's future - only mention of copd (I take the point it is their business plan to target copd but asthma was always mentioned alongside COPD). I also am not as sure as I was about vrp 700 - if results so far had been brilliant would they really have struck this deal? my only hope is that this deal was largely sealed when the price was under 2p when they cancelled Darwin - they must have had this secured. It MAY be that they have done this in the hope of far greater returns in the future but it has always been about the future for this company, never the present. I will hold because I am trapped. As always not enough detail in rns - thought these guys were different hence my, for me anyway, massive holding (at price I bought them at). May come good one day and we all hold our own views but bar this fantastic board where positive and negative views can be put without much criticism it has not been a great investment save for those buying in recently. That is an understatement
VRP's new investor, confidence. http://www.excalibur-group.co.uk/people/executive/prof-sir-chris-evans/sir-chris/
Datafeed and UK data supplied by NETbuilder and Interactive Data.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.